Clear Search

Showing 3 results for “Li J”.

January 2024

Telitacicept in Patients with Active Systemic Lupus Erythematosus: Results of A Phase 2b, Randomised, Double-blind, Placebo-controlled Trial

Ann Rheum Dis. 2023; DOI: 10.1136/ard-2023-224854

This Phase 2 trial demonstrated the efficacy and acceptable safety profile of telitacicept in patients with SLE. The safety profile of telitacicept was comparable with that observed in clinical trials of other B cell-targeting agents.

more…

May 2023
September 2022

Trajectory of Damage Accrual in Systemic Lupus Erythematosus based on Ethnicity and Socioeconomic Factors

J Rheumatol. 2022. Epub ahead of print doi: 10.3899/jrheum.211135

Large study confirms that cumulative damage accrual is faster in African-Americans, compared to Caucasians, highlighting that ethnicity plays the major role in damage accrual, regardless of socioeconomic status.

more…